Christopher L. Cioffi

2.4k total citations · 3 hit papers
53 papers, 1.6k citations indexed

About

Christopher L. Cioffi is a scholar working on Molecular Biology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Christopher L. Cioffi has authored 53 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 20 papers in Immunology and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Christopher L. Cioffi's work include Psoriasis: Treatment and Pathogenesis (20 papers), Autoimmune Bullous Skin Diseases (9 papers) and Retinoids in leukemia and cellular processes (7 papers). Christopher L. Cioffi is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (20 papers), Autoimmune Bullous Skin Diseases (9 papers) and Retinoids in leukemia and cellular processes (7 papers). Christopher L. Cioffi collaborates with scholars based in United States, United Kingdom and Belgium. Christopher L. Cioffi's co-authors include Andrew Blauvelt, Luke Peterson, Kristian Reich, Veerle Vanvoorden, Cynthia Madden, Kim Papp, Richard B. Warren, Richard G. Langley, Joseph F. Merola and Nancy Cross and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Christopher L. Cioffi

51 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bimekizumab versus Secukinumab in Plaque Psoriasis

2021 230 citations Kristian Reich, Richard B. Warren et al. profile →
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

2021 170 citations Kenneth B. Gordon, Kristian Reich et al. The Lancet profile →
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

2021 169 citations Kristian Reich, Kim Papp et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher L. Cioffi United States	20	909	480	349	331	208	53	1.6k
Kashif Ahmad United States	22	183 0.2×	151 0.3×	55 0.2×	854 2.6×	59 0.3×	58	1.5k
Peter Norman United Kingdom	18	301 0.3×	36 0.1×	135 0.4×	436 1.3×	57 0.3×	100	1.3k
Uma Yasothan United States	22	287 0.3×	23 0.0×	83 0.2×	608 1.8×	106 0.5×	30	1.4k
Johanna Ungerstedt Sweden	20	255 0.3×	38 0.1×	41 0.1×	855 2.6×	267 1.3×	40	1.4k
Jean‐Michel Rondeau Switzerland	23	182 0.2×	52 0.1×	54 0.2×	843 2.5×	33 0.2×	43	1.6k
Kenichi Higashino Japan	24	420 0.5×	25 0.1×	66 0.2×	775 2.3×	41 0.2×	35	1.6k
G. Müller Germany	10	219 0.2×	66 0.1×	87 0.2×	176 0.5×	43 0.2×	25	592
Sunanda G. Dastidar India	21	190 0.2×	39 0.1×	56 0.2×	618 1.9×	31 0.1×	56	1.4k
Fusako Nishigaki Japan	19	141 0.2×	31 0.1×	208 0.6×	469 1.4×	73 0.4×	41	1.0k

Countries citing papers authored by Christopher L. Cioffi

Since Specialization

Citations

This map shows the geographic impact of Christopher L. Cioffi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher L. Cioffi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher L. Cioffi more than expected).

Fields of papers citing papers by Christopher L. Cioffi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher L. Cioffi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher L. Cioffi. The network helps show where Christopher L. Cioffi may publish in the future.

Co-authorship network of co-authors of Christopher L. Cioffi

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher L. Cioffi. A scholar is included among the top collaborators of Christopher L. Cioffi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher L. Cioffi. Christopher L. Cioffi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Patel, Ashok R., et al.. (2024). Hybrid Pd0.1Cu0.9Co2O4 nano-flakes: a novel, efficient and reusable catalyst for the one-pot heck and Suzuki couplings with simultaneous transesterification reactions under microwave irradiation. Frontiers in Chemistry. 12. 1496234–1496234. 1 indexed citations

Wilson, Katie A., Patrick Sutton, S. Jayakumar, et al.. (2023). The efficacy of the analgesic GlyT2 inhibitor, ORG25543 , is determined by two connected allosteric sites. Journal of Neurochemistry. 168(9). 1973–1992. 5 indexed citations

Wang, Yuhong, Xiang Ma, Arun Raja, et al.. (2022). The novel visual cycle inhibitor (±)-RPE65-61 protects retinal photoreceptors from light-induced degeneration. PLoS ONE. 17(10). e0269437–e0269437. 6 indexed citations

Bafna, Khushboo, Christopher L. Cioffi, Robert M. Krug, & G.T. Montelione. (2022). Structural similarities between SARS-CoV2 3CLpro and other viral proteases suggest potential lead molecules for developing broad spectrum antivirals. Frontiers in Chemistry. 10. 948553–948553. 9 indexed citations

Warren, Richard B., et al.. (2021). Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials. Dermatology and Therapy. 11(5). 1551–1569. 9 indexed citations

Blauvelt, Andrew, Jashin J. Wu, Kristian Reich, et al.. (2021). 27380 Bimekizumab efficacy in patients with moderate to severe plaque psoriasis during the randomized withdrawal and retreatment phase of BE READY, a phase 3 trial. Journal of the American Academy of Dermatology. 85(3). AB139–AB139. 6 indexed citations

Reich, Kristian, Kim Papp, Andrew Blauvelt, et al.. (2021). Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. The Lancet. 397(10273). 487–498. 169 indexed citations breakdown →

Blauvelt, Andrew, Kim Papp, Joseph F. Merola, et al.. (2020). Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. Journal of the American Academy of Dermatology. 83(5). 1367–1374. 50 indexed citations

Blauvelt, Andrew, Joseph F. Merola, Kim Papp, et al.. (2020). 14020 Durability of responses with bimekizumab, a selective dual inhibitor of interleukin-17A and -17F, in moderate to severe chronic plaque psoriasis in a 60-week randomized, double-blinded, phase 2b study (BE ABLE 2). Journal of the American Academy of Dermatology. 83(6). AB16–AB16. 2 indexed citations

10.

Gottlieb, Alice B., et al.. (2020). Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis. Dermatology and Therapy. 10(6). 1255–1272. 6 indexed citations

11.

Ma, Zhuo, et al.. (2019). Stringent response governs the oxidative stress resistance and virulence of Francisella tularensis. PLoS ONE. 14(10). e0224094–e0224094. 19 indexed citations

12.

Moiseyev, Gennadiy, et al.. (2018). A novel RPE65 inhibitor CU239 suppresses visual cycle and prevents retinal degeneration. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1864(7). 2420–2429. 16 indexed citations

13.

Papp, Kim, Joseph F. Merola, Alice B. Gottlieb, et al.. (2018). Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. Journal of the American Academy of Dermatology. 79(2). 277–286.e10. 157 indexed citations

14.

Burmester, Gerd‐Rüdiger, Bernard Combe, Jeffrey R. Curtis, et al.. (2016). Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. The Lancet. 388(10061). 2763–2774. 134 indexed citations

15.

Cioffi, Christopher L. & Peter R. Guzzo. (2016). Inhibitors of Glycine Transporter-1: Potential Therapeutics for the Treatment of CNS Disorders. Current Topics in Medicinal Chemistry. 16(29). 3404–3437. 22 indexed citations

16.

Cioffi, Christopher L., Emily Freeman, Ping Chen, et al.. (2014). Design, Synthesis, and Evaluation of Nonretinoid Retinol Binding Protein 4 Antagonists for the Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease. Journal of Medicinal Chemistry. 57(18). 7731–7757. 42 indexed citations

17.

Cioffi, Christopher L.. (2013). Modulation of NMDA receptor function as a treatment for schizophrenia. Bioorganic & Medicinal Chemistry Letters. 23(18). 5034–5044. 23 indexed citations

18.

Manning, David D., Christopher L. Cioffi, Alexander Usyatinsky, et al.. (2010). Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome. Bioorganic & Medicinal Chemistry Letters. 21(1). 58–61. 9 indexed citations

19.

Wentland, Mark P., Christopher L. Cioffi, Yingchun Ye, et al.. (2000). 8-Aminocyclazocine analogues: synthesis and structure–activity relationships. Bioorganic & Medicinal Chemistry Letters. 10(2). 183–187. 23 indexed citations

20.

Cioffi, Christopher L., et al.. (1995). Synthesis of 24.xi.-Squalamine, an Anti-Infective Steroidal Polyamine. The Journal of Organic Chemistry. 60(16). 5121–5126. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact